Charles Thompson, MD
Pulmonary Disease · Anderson, SCNPI 1851394597
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,307 of the $24,126 with a category attached, or 84.2%. It is spread thinly across 57 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $6,176 and has fallen 51.6% since, to $2,988 in 2025.
Across 1,053 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$3K
- Chiesi USA, Inc.$2K
- Boehringer Ingelheim$2K
- Merck$2K
- Boehringer Ingelheim International GmbH$2K
- plus $12K from 51 others
Across 2,846 payments — averaging $2733.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.5M
- GSK$776K
- Boehringer Ingelheim$765K
- AstraZeneca$605K
- Eli Lilly$377K
- Bavarian Nordic A/s$331K
- plus $1.4M from 21 others
What the payments were for
- Consulting fees$140%
- Travel & lodging$3,34514%
- Food & beverage$20,30784%
- Education$4602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,126 in reported general payments places this provider in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZemairaAlpha-1-Proteinase Inhibitor | 33 | $536,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 611 | $527,863 |
| OpsumitMacitentan | 39 | $499,410 |
| NucalaMepolizumab | 103 | $450,709 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 29 | $405,709 |
| WakixPitolisant Hcl | 28 | $342,693 |
| UptraviSelexipag | 13 | $304,900 |
| OfevNintedanib Esylate | 20 | $285,500 |
| Tyvaso Refill KitTreprostinil/Neb Accessories | 12 | $256,062 |
| GlassiaAlpha-1-Proteinase Inhibitor | 22 | $247,536 |
| Dupixent PenDupilumab | 56 | $234,329 |
| AdempasRiociguat | 12 | $170,065 |
| Fasenra PenBenralizumab | 20 | $119,058 |
| TezspireTezepelumab-Ekko | 19 | $88,255 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $75,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,080 | $1,117,3781,002 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $633 | $804,31152 claims |
| CSL BehringZemaira | $199 | $536,24233 claims |
| Grifols USA, LLCProlastin C | $1,124 | $405,70929 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,734 | $399,355187 claims |
| Harmony Biosciences LLCWakix | $106 | $342,69328 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia, Gammagard Liquid | $1,231 | $306,00634 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $2,516 | $209,511226 claims |
| PfizerEliquis | $49 | $33,65743 claims |
| Johnson & JohnsonXarelto | $24 | $18,01725 claims |
| MerckDulera | $1,610 | $8,20214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Anderson
- Abhijit RavalAnderson$2M
- Kenneth WaltersAnderson$81K
- Syed MalikAnderson$10K
- Emerald Rose BranchAnderson$8K
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.